Physician profile
Robert J Bierwirth
NPI 1053517565
$603,235.79
in general payments reported to CMS, 2019-2025
38 companies · $190K in 2025
The $190K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $34K · 2021: $50K · 2022: $69K · 2023: $40K · 2024: $129K · 2025: $190K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $297K · Travel and Lodging: $28K · Food and Beverage: $22K · Consulting Fee: $8,145 · Honoraria: $3,870 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $296,841.36 |
| Travel and Lodging | $27,874.72 |
| Food and Beverage | $22,249.23 |
| Consulting Fee | $8,145.00 |
| Honoraria | $3,870.00 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $183,047.27 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $94,464.03 | 2019-2025 | Epclusa |
| Abbvie INC. | $77,352.64 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Scientific Affairs, LLC | $70,474.61 | 2019-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $55,537.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $49,557.30 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $16,730.55 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $14,889.30 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14,773.97 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $8,075.15 | 2019-2025 | Entyvio, Eohilia |
| Allergan, INC. | $6,808.61 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $3,182.00 | 2025 | Iqirvo |
| Celgene Corporation | $1,602.75 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $1,373.81 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $1,057.50 | 2025 | Imfinzi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $771.99 | 2019-2025 | |
| Qol Medical, LLC | $723.42 | 2019-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $330.93 | 2021-2022 | |
| Boston Scientific Corporation | $282.73 | 2019-2024 | Spyglass |
| Ardelyx, INC. | $282.32 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $251.12 | 2019-2023 | Dificid, Zinplava |
| Redhill Biopharma INC. | $232.84 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $231.51 | 2023-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $220.73 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $207.39 | 2021-2025 | Suflave, Sutab |
| Genzyme Corporation | $199.03 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $123.03 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $83.93 | 2023-2025 | Givlaari |
| Celltrion USA INC. | $75.47 | 2025 | Vegzelma |
| Ucb, INC. | $64.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $59.63 | 2023-2025 | Dupixent |
| Covidien Lp | $51.97 | 2019 | |
| Aimmune Therapeutics, INC. | $43.31 | 2025 | Vowst, Zenpep |
| Erbe USA INC | $20.36 | 2019 | |
| Organon LLC | $18.22 | 2024 | |
| Shionogi INC | $13.60 | 2019 | |
| Cook Medical LLC | $12.73 | 2019 | |
| Romark Laboratories, Lc | $8.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bierwirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.